New data finds AstraZeneca booster generates higher antibodies against Omicron

22
5
Favorite

New data finds AstraZeneca booster generates higher antibodies against Omicron

Reuters2022-01-13

Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（5）

Bluem
·2022-01-13
Hmm
Reply
1
Report
imsomeonelse
·2022-01-13
Sometimes just don’t know what to trust anymore haha
Reply
2
Report
DingDang
·2022-01-13
Buy!
Reply
3
Report
LennartM
·2022-01-13
like pls
Reply
6
Report
rabbit0112
·2022-01-13
Like
Reply
5
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2203768409?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-13 16:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2203768409","market":"us","top_or_hot":-1,"title":"New data finds AstraZeneca booster generates higher antibodies against Omicron","media":"Reuters","content":"<div>\n<p>Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New data finds AstraZeneca booster generates higher antibodies against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew data finds AstraZeneca booster generates higher antibodies against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-13 16:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4017","symbol_name":"黄金","start_time":0,"source_url":"https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html","article_id":"2203768409","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2203768409","pubTimestamp":1642062662,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its CO","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4017":"黄金","PFE":"辉瑞","AZN":"阿斯利康"},"translate_title":"新数据发现阿斯利康增强剂产生更高的抗奥密克戎抗体","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9,"PFE":0.9},"content_text":"Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose.The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.The data is the first released by the company from its trials into boosters of its vaccine.The company said it adds to the growing evidence that supports a third dose of its vaccine irrespective of the primary vaccination schedule.\"These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19,\" Oxford Vaccine Group chief Andrew Pollard said in a statement.A major British trial in December found that AstraZeneca's shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer's, which is based on mRNA technology.However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9002416496,"gmtCreate":1642067042436,"gmtModify":1676533677570,"author":{"id":"3575980094521663","authorId":"3575980094521663","name":"Bluem","avatar":"https://static.tigerbbs.com/2ea0046117889d9c87b13a313a480e69","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":3,"crmLevelSwitch":0},"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002416496","repostId":2203768409,"repostType":4,"repost":{"id":"2203768409","pubTimestamp":1642062662,"share":"https://www.laohu8.com/m/news/2203768409?lang=&edition=full","pubTime":"2022-01-13 16:31","market":"us","language":"en","title":"New data finds AstraZeneca booster generates higher antibodies against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=2203768409","media":"Reuters","summary":"Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its CO","content":"<html><head></head><body><p>Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose.</p><p>The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.</p><p>AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.</p><p>The data is the first released by the company from its trials into boosters of its vaccine.</p><p>The company said it adds to the growing evidence that supports a third dose of its vaccine irrespective of the primary vaccination schedule.</p><p>&#34;These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19,&#34; Oxford Vaccine Group chief Andrew Pollard said in a statement.</p><p>A major British trial in December found that AstraZeneca&#39;s shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer&#39;s, which is based on mRNA technology.</p><p>However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New data finds AstraZeneca booster generates higher antibodies against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew data finds AstraZeneca booster generates higher antibodies against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-13 16:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","AZN":"阿斯利康","BK4017":"黄金"},"source_url":"https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2203768409","content_text":"Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose.The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.The data is the first released by the company from its trials into boosters of its vaccine.The company said it adds to the growing evidence that supports a third dose of its vaccine irrespective of the primary vaccination schedule.\"These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19,\" Oxford Vaccine Group chief Andrew Pollard said in a statement.A major British trial in December found that AstraZeneca's shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer's, which is based on mRNA technology.However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9002411126,"gmtCreate":1642066238074,"gmtModify":1676533677446,"author":{"id":"3572697049328629","authorId":"3572697049328629","name":"imsomeonelse","avatar":"https://community-static.tradeup.com/news/4c0e0e71f2bf68f6fb5622004a9e309d","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":7,"crmLevelSwitch":0},"htmlText":"Sometimes just don’t know what to trust anymore haha","listText":"Sometimes just don’t know what to trust anymore haha","text":"Sometimes just don’t know what to trust anymore haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002411126","repostId":2203768409,"repostType":4,"repost":{"id":"2203768409","pubTimestamp":1642062662,"share":"https://www.laohu8.com/m/news/2203768409?lang=&edition=full","pubTime":"2022-01-13 16:31","market":"us","language":"en","title":"New data finds AstraZeneca booster generates higher antibodies against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=2203768409","media":"Reuters","summary":"Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its CO","content":"<html><head></head><body><p>Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose.</p><p>The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.</p><p>AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.</p><p>The data is the first released by the company from its trials into boosters of its vaccine.</p><p>The company said it adds to the growing evidence that supports a third dose of its vaccine irrespective of the primary vaccination schedule.</p><p>&#34;These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19,&#34; Oxford Vaccine Group chief Andrew Pollard said in a statement.</p><p>A major British trial in December found that AstraZeneca&#39;s shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer&#39;s, which is based on mRNA technology.</p><p>However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New data finds AstraZeneca booster generates higher antibodies against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew data finds AstraZeneca booster generates higher antibodies against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-13 16:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","AZN":"阿斯利康","BK4017":"黄金"},"source_url":"https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2203768409","content_text":"Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose.The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.The data is the first released by the company from its trials into boosters of its vaccine.The company said it adds to the growing evidence that supports a third dose of its vaccine irrespective of the primary vaccination schedule.\"These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19,\" Oxford Vaccine Group chief Andrew Pollard said in a statement.A major British trial in December found that AstraZeneca's shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer's, which is based on mRNA technology.However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9002437086,"gmtCreate":1642064658954,"gmtModify":1676533677352,"author":{"id":"3553254172092293","authorId":"3553254172092293","name":"DingDang","avatar":"https://static.tigerbbs.com/d2a0c38ce6f3c2661fa15b7d1f52eeaf","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Buy!","listText":"Buy!","text":"Buy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002437086","repostId":2203768409,"repostType":4,"repost":{"id":"2203768409","pubTimestamp":1642062662,"share":"https://www.laohu8.com/m/news/2203768409?lang=&edition=full","pubTime":"2022-01-13 16:31","market":"us","language":"en","title":"New data finds AstraZeneca booster generates higher antibodies against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=2203768409","media":"Reuters","summary":"Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its CO","content":"<html><head></head><body><p>Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose.</p><p>The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.</p><p>AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.</p><p>The data is the first released by the company from its trials into boosters of its vaccine.</p><p>The company said it adds to the growing evidence that supports a third dose of its vaccine irrespective of the primary vaccination schedule.</p><p>&#34;These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19,&#34; Oxford Vaccine Group chief Andrew Pollard said in a statement.</p><p>A major British trial in December found that AstraZeneca&#39;s shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer&#39;s, which is based on mRNA technology.</p><p>However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New data finds AstraZeneca booster generates higher antibodies against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew data finds AstraZeneca booster generates higher antibodies against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-13 16:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","AZN":"阿斯利康","BK4017":"黄金"},"source_url":"https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2203768409","content_text":"Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose.The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.The data is the first released by the company from its trials into boosters of its vaccine.The company said it adds to the growing evidence that supports a third dose of its vaccine irrespective of the primary vaccination schedule.\"These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19,\" Oxford Vaccine Group chief Andrew Pollard said in a statement.A major British trial in December found that AstraZeneca's shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer's, which is based on mRNA technology.However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9002432174,"gmtCreate":1642063462521,"gmtModify":1676533677279,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002432174","repostId":2203768409,"repostType":4,"repost":{"id":"2203768409","pubTimestamp":1642062662,"share":"https://www.laohu8.com/m/news/2203768409?lang=&edition=full","pubTime":"2022-01-13 16:31","market":"us","language":"en","title":"New data finds AstraZeneca booster generates higher antibodies against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=2203768409","media":"Reuters","summary":"Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its CO","content":"<html><head></head><body><p>Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose.</p><p>The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.</p><p>AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.</p><p>The data is the first released by the company from its trials into boosters of its vaccine.</p><p>The company said it adds to the growing evidence that supports a third dose of its vaccine irrespective of the primary vaccination schedule.</p><p>&#34;These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19,&#34; Oxford Vaccine Group chief Andrew Pollard said in a statement.</p><p>A major British trial in December found that AstraZeneca&#39;s shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer&#39;s, which is based on mRNA technology.</p><p>However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New data finds AstraZeneca booster generates higher antibodies against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew data finds AstraZeneca booster generates higher antibodies against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-13 16:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","AZN":"阿斯利康","BK4017":"黄金"},"source_url":"https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2203768409","content_text":"Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose.The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.The data is the first released by the company from its trials into boosters of its vaccine.The company said it adds to the growing evidence that supports a third dose of its vaccine irrespective of the primary vaccination schedule.\"These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19,\" Oxford Vaccine Group chief Andrew Pollard said in a statement.A major British trial in December found that AstraZeneca's shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer's, which is based on mRNA technology.However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9002436595,"gmtCreate":1642063172489,"gmtModify":1676533677264,"author":{"id":"4088071561934010","authorId":"4088071561934010","name":"rabbit0112","avatar":"https://static.tigerbbs.com/f34a76da0c81813be84eb946d69d797f","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002436595","repostId":2203768409,"repostType":4,"repost":{"id":"2203768409","pubTimestamp":1642062662,"share":"https://www.laohu8.com/m/news/2203768409?lang=&edition=full","pubTime":"2022-01-13 16:31","market":"us","language":"en","title":"New data finds AstraZeneca booster generates higher antibodies against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=2203768409","media":"Reuters","summary":"Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its CO","content":"<html><head></head><body><p>Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose.</p><p>The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.</p><p>AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.</p><p>The data is the first released by the company from its trials into boosters of its vaccine.</p><p>The company said it adds to the growing evidence that supports a third dose of its vaccine irrespective of the primary vaccination schedule.</p><p>&#34;These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19,&#34; Oxford Vaccine Group chief Andrew Pollard said in a statement.</p><p>A major British trial in December found that AstraZeneca&#39;s shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer&#39;s, which is based on mRNA technology.</p><p>However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New data finds AstraZeneca booster generates higher antibodies against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew data finds AstraZeneca booster generates higher antibodies against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-13 16:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","AZN":"阿斯利康","BK4017":"黄金"},"source_url":"https://finance.yahoo.com/news/1-data-finds-astrazeneca-booster-080725069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2203768409","content_text":"Jan 13 (Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose.The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.The data is the first released by the company from its trials into boosters of its vaccine.The company said it adds to the growing evidence that supports a third dose of its vaccine irrespective of the primary vaccination schedule.\"These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19,\" Oxford Vaccine Group chief Andrew Pollard said in a statement.A major British trial in December found that AstraZeneca's shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer's, which is based on mRNA technology.However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":22,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}